

### **Array hires VP of clinical development**

BOULDER - Array BioPharma Inc. has created a new job to oversee the Boulder-based biopharma's efforts in human clinical development of its drugs to treat cancer and inflammatory diseases.

Array (Nasdaq: ARRY) has hired Dr. Bengt Bergstrom as vice president of clinical development to lead clinical science and drug safety activities for the company's growing pipeline of targeted small molecule drugs.

"We are very pleased to have someone of Bengt's caliber leading our clinical development group," said Robert E. Conway, chief executive officer. "Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda, will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development."

Bergstrom has more than 17 years experience working in the pharmaceutical industry. He's held various leadership positions within drug development, project management, strategic marketing and business development, and clinical sciences at Hoffmann-La Roche.

Over the years, he led programs for small molecules, biologics and gene therapy in various therapeutic areas including oncology, inflammation, diabetes, metabolism and neurology. He has experience with phase 1 through 4 clinical trials and has worked with regulatory agencies around the world.